

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3474.1001-011

APPLICATION NO.
10/791,223

**SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

FIRST NAMED INVENTOR
Mel H. Epstein

FILING DATE
March 2, 2004


EXAMINER
Brian S. Kwon

CONFIRMATION NO.
3953

GROUP
1614

April 25, 2007

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

[illegible]


721384_1

EXAMINER

/Brian-Yong Kwon/

DATE CONSIDERED _____

07/19/2007

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION  March 5, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO. 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/B.K./	C269	Chertkow, H., "Mild Cognitive Impairment," <i>Curr. Opin. in Neurol.</i> 15:401-407 (2002).
	C270	Clarke, A., "A New Formulation of Selegiline: Improved Bioavailability and Selectivity for MAO-B Inhibition," <i>J. Neural. Transm.</i> 110:1241-1255 (2003).
	C271	Gauthier, S., <i>et al.</i> , "Mild Cognitive Impairment," <i>The Lancet</i> 367:1262-1270 (2006).
	C272	Grundman, M., <i>et al.</i> , "Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials," <i>Arch. Neurol.</i> 61:59-66 (2004).
	C273	Halgren, E., <i>et al.</i> , "Human Hippocampal Formation EEG Desynchronizes During Attentiveness and Movement," <i>Electroencephalography and Clinical Neurophysiology</i> 44:778-781 (1978).
	C274	Lynch, G., <i>et al.</i> , "The Nature and Causes of Hippocampal Long-term Potentiation," <i>Progress in Brain Research</i> 83:233-250 (1990).
	C275	Mild Cognitive Impairment. Alzheimer's Society Information Sheet [online], March 2005. Retrieved from the Internet <URL: http://www.alzheimers.org.uk >.
	C276	Mild Cognitive Impairment-Alzheimer's Disease Part XVI [online], November 2006 [retrieved on 2007-01-24]. Retrieved from the Internet <URL: http://www.therubins.com >.
	C277	Meeker, J.S. and Reynolds, P.C., "Postmortem Tissue Methamphetamine Concentrations Following Selegiline Administration," <i>J. of Analytical Toxicology</i> 14:330-331 (1990).
	C278	Nickel, B., <i>et al.</i> , "Evaluation of Physical Dependence Liability of <i>l</i> -deprenyl (Selegiline) in Animals," <i>Clinical Pharmacology & Therapeutics</i> , 56(6):757-767 (1994).
	C279	Petersen, R.C., <i>et al.</i> , "Current Concepts in Mild Cognitive Impairment," <i>Arch Neurol.</i> 58:1985-1992 (2001).
	C280	Uchida, S., <i>et al.</i> , "Cortical Oscillations in Human Medial Temporal Lobe During Wakefulness and All-night Sleep," <i>Brain Research</i> 891:7-19 (2001).
	C281	Yasar, S., <i>et al.</i> , "Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(-)-Deprenyl]," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 317(1):387-394 (2006).
✓	C282	Kwon, Y. S., <i>et al.</i> , "Selegiline Potentiates the Effects of Egb 761 in Response to Ischemic Brain Injury," <i>Neurochemistry International</i> 45:157-170 (2004).

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 07/19/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 5, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO. 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. 3953	GROUP 1614	

/B.K./	C283	Semkova, I., <i>et al.</i> , "Selegiline Enhances NGF Synthesis and Protects Central Nervous System Neurons from Excitotoxic and Ischemic Damage," <i>European Journal of Pharmacology</i> 315:19-30 (1996).
/B.K./	C284	Sivenius, J., <i>et al.</i> , "Selegiline Treatment Facilitates Recovery After Stroke," <i>Neurorehabilitation and Neural Repair</i> 15:183-190 (2001).

697835_1.DOC

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 07/19/2007
-------------------------------	-----------------------------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 4, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO. 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Brian S. Kwon		CONFIRMATION NO. 3953	GROUP 1614

[illegible]

EXAMINER	DATE CONSIDERED
/Brian-Yong Kwon/	07/19/2007